FEMY Quote, Financials, Valuation and Earnings

Armata Pharmaceuticals, Inc. has a net margin of -575.1% compared to Femasys, Inc.'s net margin of -2301.55%. Femasys, Inc.'s return on equity of -606.11% beat Armata Pharmaceuticals, Inc.'s return on equity of --.

Femasys, Inc. has a consensus price target of $5.17, signalling upside risk potential of 504.22%. On the other hand Armata Pharmaceuticals, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 55.98%. Given that Femasys, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Femasys, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Femasys, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Armata Pharmaceuticals, Inc. has a beta of 1.240, suggesting its more volatile than the S&P 500 by 23.97%.

Femasys, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Armata Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Femasys, Inc. pays -- of its earnings as a dividend. Armata Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Femasys, Inc. quarterly revenues are $729.4K, which are smaller than Armata Pharmaceuticals, Inc. quarterly revenues of $1.2M. Femasys, Inc.'s net income of -$4.2M is higher than Armata Pharmaceuticals, Inc.'s net income of -$26.7M. Notably, Femasys, Inc.'s price-to-earnings ratio is -- while Armata Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Femasys, Inc. is 12.22x versus 47.86x for Armata Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Perspective Therapeutics, Inc. has a net margin of -575.1% compared to Femasys, Inc.'s net margin of -12425.36%. Femasys, Inc.'s return on equity of -606.11% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.

Femasys, Inc. has a consensus price target of $5.17, signalling upside risk potential of 504.22%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 355.84%. Given that Femasys, Inc. has higher upside potential than Perspective Therapeutics, Inc., analysts believe Femasys, Inc. is more attractive than Perspective Therapeutics, Inc..

Femasys, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.

Femasys, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Femasys, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.

Femasys, Inc. quarterly revenues are $729.4K, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. Femasys, Inc.'s net income of -$4.2M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Femasys, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Femasys, Inc. is 12.22x versus 183.07x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -575.1% compared to Femasys, Inc.'s net margin of 13.19%. Femasys, Inc.'s return on equity of -606.11% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Femasys, Inc. has a consensus price target of $5.17, signalling upside risk potential of 504.22%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 501.09%. Given that Femasys, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Femasys, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Femasys, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Femasys, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Femasys, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Femasys, Inc. quarterly revenues are $729.4K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Femasys, Inc.'s net income of -$4.2M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Femasys, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 26.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Femasys, Inc. is 12.22x versus 2.33x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Quantum-Si, Inc. has a net margin of -575.1% compared to Femasys, Inc.'s net margin of -6467.94%. Femasys, Inc.'s return on equity of -606.11% beat Quantum-Si, Inc.'s return on equity of -51.75%.

Femasys, Inc. has a consensus price target of $5.17, signalling upside risk potential of 504.22%. On the other hand Quantum-Si, Inc. has an analysts' consensus of $2.85 which suggests that it could grow by 103.57%. Given that Femasys, Inc. has higher upside potential than Quantum-Si, Inc., analysts believe Femasys, Inc. is more attractive than Quantum-Si, Inc..

Femasys, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Quantum-Si, Inc. has a beta of 2.983, suggesting its more volatile than the S&P 500 by 198.267%.

Femasys, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quantum-Si, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Femasys, Inc. pays -- of its earnings as a dividend. Quantum-Si, Inc. pays out -- of its earnings as a dividend.

Femasys, Inc. quarterly revenues are $729.4K, which are larger than Quantum-Si, Inc. quarterly revenues of $552K. Femasys, Inc.'s net income of -$4.2M is higher than Quantum-Si, Inc.'s net income of -$35.7M. Notably, Femasys, Inc.'s price-to-earnings ratio is -- while Quantum-Si, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Femasys, Inc. is 12.22x versus 79.46x for Quantum-Si, Inc.. Usually stocks with elevated PS ratios are considered overvalued.